Ensitrelvir fumarate

• CAS: 2757470-18-9
• Catalog Number: ACM2757470189
• Category: Inhibitors
• Molecular Weight: 647.96
• Molecular Formula: C26H21ClF3N9O6
• Description: Ensitrelvir, also known as S-217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM). It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.
• Synonyms: Ensitrelvir fumarate; S-217622; S 217622; S217622; Xocova
• IUPAC Name: (E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione fumaric acid
• Canonical SMILES: O=C(N(CC1=NN(C)C=N1)C(N/2)=O)N(CC3=CC(F)=C(F)C=C3F)C2=N\C4=CC5=CN(C)N=C5C=C4Cl.O=C(O)/C=C/C(O)=O
• InChI: InChI=1S/C22H17ClF3N9O2.C4H4O4/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24;5-3(6)1-2-4(7)8/h3-7,10H,8-9H2,1-2H3,(H,28,29,36);1-2H,(H,5,6)(H,7,8)/b;2-1+
• InChI Key: FBOCUALVLIWPNQ-WLHGVMLRSA-N
• Solubility: To be determined
• Appearance: Solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 2647530-73-0 (free base); 2757470-18-9 (fumarate)
• Biological Target: Ensitrelvir (S-217622) fumarate is an active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
• Drug Formulation: To be determined
• Elemental Analysis: C, 48.20; H, 3.27; Cl, 5.47; F, 8.80; N, 19.46; O, 14.81
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: The antiviral activities were evaluated as per their inhibitory ability of the cytopathic effects elicited in SARS-CoV-2-infected; VeroE6/TMPRSS2 cells. S-217622 exhibited similar antiviral activities against all tested SARS-CoV-2 variants, including the; Omicron strain, which is responsible for the current wave of the pandemic, indicating its potential broad usability as a therapeutic; agent for treating COVID-19 (half-maximal effective concentration [EC50] = 0.29-0.50 μM. Antiviral activity of S-217622 against; SARS-CoV (EC50 = 0.21 μM). was also comparable to that against SARS-CoV-2, where the sequence homology of 3CLpro between; SARS-CoV-2 and SARS-CoV was well-conserved. S-217622 also exhibited potent antiviral activity against MERS-CoV (EC50 = 1.4; μM), HCoV-OC43 (EC90 = 0.074 μM), and HCoV-229E (EC50 = 5.5 μM). S-217622 showed no inhibitory activity against host-cell; proteases, such as caspase-2, chymotrypsin, cathepsin B/D/G/L, and thrombin at up to 100 μM, suggesting its high selectivity for; coronavirus proteases. S-217622 exhibited no safety concerns in vitro in studies involving ether-a-go-go-related gene inhibition,; mutagenicity/clastogenicity, and phototoxicity.; Reference: J Med Chem. 2022 May 12;65(9):6499-6512. https://pubmed.ncbi.nlm.nih.gov/35352927/
• In Vivo Activity: The antiviral efficacy of S-217622 was evaluated in vivo in mice infected with SARS-CoV-2 Gamma strain. Five-week-old BALB/c; mice were intranasally inoculated with SARS-CoV-2 Gamma strain (hCoV-19/Japan/TY7-501/2021), and S-217622 was administered; orally as a 0.5% methylcellulose suspension immediately and 12 hours after infection. S-217622 treatment reduced the intrapulmonary; viral titers dose-dependently. The mean viral titer was significantly lower in the S-217622 treatment groups than in the vehicle; treatment group (2 mg/kg vs vehicle, p = 0.0289; 8, 16, and 32 mg/kg vs vehicle, p < 0.0001). Viral titers reached near the lower limit; of quantification (1.80 - log10 50% tissue culture infectious dose [TCID50]/mL) at 16 and 32 mg/kg in the S-217622 treatment group.; Although twice-daily treatment was applied in this mouse model, a once-daily treatment model could be applicable in clinical; treatment because S-217622 showed a much lower clearance and longer elimination half-lives in nonrodents than in rodents.; Reference: J Med Chem. 2022 May 12;65(9):6499-6512. https://pubmed.ncbi.nlm.nih.gov/35352927/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).